Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018

  • ID: 4529328
  • Drug Pipelines
  • 302 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abeome Corp
  • Boehringer Ingelheim GmbH
  • FibroStatin SL
  • Kasiak Research Pvt Ltd
  • OliX Pharmaceuticals Inc
  • Samumed LLC
  • MORE
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights:

This latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 15, 17, 1, 67 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeome Corp
  • Boehringer Ingelheim GmbH
  • FibroStatin SL
  • Kasiak Research Pvt Ltd
  • OliX Pharmaceuticals Inc
  • Samumed LLC
  • MORE
Introduction

Idiopathic Pulmonary Fibrosis - Overview

Idiopathic Pulmonary Fibrosis - Therapeutics Development

Idiopathic Pulmonary Fibrosis - Therapeutics Assessment

Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development

Idiopathic Pulmonary Fibrosis - Drug Profiles

Idiopathic Pulmonary Fibrosis - Dormant Projects

Idiopathic Pulmonary Fibrosis - Discontinued Products

Idiopathic Pulmonary Fibrosis - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Universities/Institutes, H1 2018

Table 8: Products under Development by Companies, H1 2018

Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 14: Products under Development by Universities/Institutes, H1 2018

Table 15: Number of Products by Stage and Target, H1 2018

Table 16: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 17: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Table 18: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Table 19: Number of Products by Stage and Mechanism of Action, H1 2018

Table 20: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 21: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Table 22: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Table 23: Number of Products by Stage and Route of Administration, H1 2018

Table 24: Number of Products by Stage and Molecule Type, H1 2018

Table 25: Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2018

Table 26: Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2018

Table 27: Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018

Table 28: Idiopathic Pulmonary Fibrosis - Pipeline by Allinky Biopharma, H1 2018

Table 29: Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2018

Table 30: Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H1 2018

Table 31: Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Corp, H1 2018

Table 32: Idiopathic Pulmonary Fibrosis - Pipeline by BerGenBio ASA, H1 2018

Table 33: Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H1 2018

Table 34: Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H1 2018

Table 35: Idiopathic Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Table 36: Idiopathic Pulmonary Fibrosis - Pipeline by BreStem Therapeutics Inc, H1 2018

Table 37: Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Co, H1 2018

Table 38: Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H1 2018

Table 39: Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2018

Table 40: Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H1 2018

Table 41: Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H1 2018

Table 42: Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Table 43: Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H1 2018

Table 44: Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H1 2018

Table 45: Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2018

Table 46: Idiopathic Pulmonary Fibrosis - Pipeline by Galecto Biotech AB, H1 2018

Table 47: Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H1 2018

Table 48: Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2018

Table 49: Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

Table 50: Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H1 2018

Table 51: Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H1 2018

Table 52: Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H1 2018

Table 53: Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2018

Table 54: Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H1 2018

Table 55: Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt Ltd, H1 2018

Table 56: Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Table 57: Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H1 2018

Table 58: Idiopathic Pulmonary Fibrosis - Pipeline by Medicenna Therapeutics Corp, H1 2018

Table 59: Idiopathic Pulmonary Fibrosis - Pipeline by Merck & Co Inc, H1 2018

Table 60: Idiopathic Pulmonary Fibrosis - Pipeline by Miragen Therapeutics Inc, H1 2018

Table 61: Idiopathic Pulmonary Fibrosis - Pipeline by Mission Therapeutics Ltd, H1 2018

Table 62: Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix Inc, H1 2018

Table 63: Idiopathic Pulmonary Fibrosis - Pipeline by Novartis AG, H1 2018

Table 64: Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H1 2018

Table 65: Idiopathic Pulmonary Fibrosis - Pipeline by Nuformix Plc, H1 2018

Table 66: Idiopathic Pulmonary Fibrosis - Pipeline by OliX Pharmaceuticals Inc, H1 2018

Table 67: Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Ltd, H1 2018

Table 68: Idiopathic Pulmonary Fibrosis - Pipeline by Promedior Inc, H1 2018

Table 69: Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2018

Table 70: Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix Inc, H1 2018

Table 71: Idiopathic Pulmonary Fibrosis - Pipeline by Re-Pharm Ltd, H1 2018

Table 72: Idiopathic Pulmonary Fibrosis - Pipeline by Redx Pharma Plc, H1 2018

Table 73: Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H1 2018

Table 74: Idiopathic Pulmonary Fibrosis - Pipeline by Reviva Pharmaceuticals Inc, H1 2018

Table 75: Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc, H1 2018

Table 76: Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma LLC, H1 2018

Table 77: Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H1 2018

Table 78: Idiopathic Pulmonary Fibrosis - Pipeline by Shionogi & Co Ltd, H1 2018

Table 79: Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics Inc, H1 2018

Table 80: Idiopathic Pulmonary Fibrosis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Table 81: Idiopathic Pulmonary Fibrosis - Pipeline by Telocyte LLC, H1 2018

Table 82: Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics Inc, H1 2018

Table 83: Idiopathic Pulmonary Fibrosis - Pipeline by Unity Biotechnology Inc, H1 2018

Table 84: Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H1 2018

Table 85: Idiopathic Pulmonary Fibrosis - Pipeline by X-Rx Inc, H1 2018

Table 86: Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corp, H1 2018

Table 87: Idiopathic Pulmonary Fibrosis - Pipeline by Zai Lab Ltd, H1 2018

Table 88: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018

Table 89: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 90: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..2), H1 2018

Table 91: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..3), H1 2018

Table 92: Idiopathic Pulmonary Fibrosis - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abeome Corp
  • AdAlta Ltd
  • Aeolus Pharmaceuticals Inc
  • Allinky Biopharma
  • AnaMar AB
  • apceth Biopharma GmbH
  • Asahi Kasei Corp
  • BerGenBio ASA
  • Biogen Inc
  • Bioneer Corp
  • Boehringer Ingelheim GmbH
  • BreStem Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Chiesi Farmaceutici SpA
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • FibroStatin SL
  • Galapagos NV
  • Galecto Biotech AB
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Global Blood Therapeutics Inc
  • iBio Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Kasiak Research Pvt Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lung Therapeutics Inc
  • Medicenna Therapeutics Corp
  • Merck & Co Inc
  • Miragen Therapeutics Inc
  • Mission Therapeutics Ltd
  • Moerae Matrix Inc
  • Novartis AG
  • Nuevolution AB
  • Nuformix Plc
  • OliX Pharmaceuticals Inc
  • Pharmaxis Ltd
  • Promedior Inc
  • ProMetic Life Sciences Inc
  • Pulmatrix Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Respira Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Ribomic Inc
  • Saje Pharma LLC
  • Samumed LLC
  • Shionogi & Co Ltd
  • Sorrento Therapeutics Inc
  • Taiho Pharmaceutical Co Ltd
  • Telocyte LLC
  • Therabron Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB
  • X-Rx Inc
  • Yuhan Corp
  • Zai Lab Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll